Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Di, Liu, Yangyang, Li, Xiaoting, Liu, Yiying, Yang, Qifan, Liu, Yuting, Wu, Jingjing, Tian, Chen, Zeng, Yulan, Zhao, Zhikun, Xiao, Yajie, Gu, Feifei, Zhang, Kai, Hu, Yue, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390822/
https://www.ncbi.nlm.nih.gov/pubmed/32793190
http://dx.doi.org/10.3389/fimmu.2020.01366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390822/
https://www.ncbi.nlm.nih.gov/pubmed/32793190
http://dx.doi.org/10.3389/fimmu.2020.01366

Ejemplares similares